Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Kiadis makes nothing into €325m
Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.
Curevac rides the Covid wave
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
A swift big pharma endorsement for Kiadis
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
Legend joins the billion-dollar club
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Bloated on arrival? Biotech's weightiest new issues
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Kiadis moves to reduce reliance on its in-house lead
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
